AKBA Shares Outstanding History
Below is a table of the AKBA shares outstanding history going back to 3/20/2014:

Date AKBA Shares Outstanding
3/20/201418.29M
4/30/201420.26M
7/31/201420.26M
10/30/201420.34M
2/28/201520.37M
5/1/201528.84M
7/31/201528.88M
11/5/201530.63M
3/1/201637.94M
4/30/201637.98M
7/31/201638.01M
10/31/201638.32M
3/1/201738.83M
4/30/201738.86M
7/31/201747.15M
10/31/201747.27M
3/1/201848.35M
4/30/201856.88M
7/31/201857.05M
10/31/201857.06M
3/15/2019117.12M
4/30/2019117.86M
7/31/2019118.86M
10/31/2019118.94M
3/1/2020129.86M
4/30/2020130.27M
7/31/2020143.32M
10/30/2020144.54M
2/19/2021153.50M
4/30/2021160.12M

Also see: AKBA Market Cap History
AKBA YTD Return
AKBA Historical Shares Outstanding:
+35.64% CAGR
AKBA Historical Shares Outstanding: +35.64% CAGR

Mouse over chart for data details
3/20/2014 ...4/30/2021
Akebia Therapeutics is a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease. Co.'s portfolio includes: Vadadustat, which is an investigational, oral hypoxia-inducible factor prolyl hydroxylase inhibitor for two indications, anemia due to chronic kidney disease (CKD), in adult patients on dialysis, and anemia due to CKD in adult patients not on dialysis; and Auryxia® (ferric citrate), for the control of serum phosphorus levels in adult patients on dialysis, or the Hyperphosphatemia Indication, and the treatment of iron deficiency anemia (IDA) in adult patients not on dialysis, or the IDA Indication; We show 30 historical shares outstanding datapoints in our coverage of AKBA's shares outstanding history.

Understanding the changing numbers of AKBA shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like AKBA versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching AKBA by allowing them to research AKBA shares outstanding history as well as any other stock in our coverage universe.
Quotes delayed 20 minutes
Get Free SEC filing alerts for AKBA:
AKBA SEC Filing Email Alerts ServiceExternal link
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Shares Outstanding Importance


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Akebia Therapeutics (AKBA) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:

AKCA Shares Outstanding History
AKER Shares Outstanding History
AKRX Shares Outstanding History
ALBO Shares Outstanding History
ALC Shares Outstanding History
ALDR Shares Outstanding History
ALDX Shares Outstanding History
ALGN Shares Outstanding History
ALIM Shares Outstanding History
ALKS Shares Outstanding History
More Healthcare companies »

 

AKBA Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2021, All Rights Reserved

Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.